SCHEMBL6510115

SCHEMBL6510115

CCc1cccc(C(C=O)c2ccnc(F)c2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
CTSA P10619 1/20 0.33
PTGS2 P35354 1/20 0.32
CYP3A4 P08684 2/20 0.32
TSHR P16473 2/20 0.32
KCNQ2 O43526 1/20 0.32
ALOX15 P16050 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
KCNH2 Q12809 1/20 0.32
ROCK2 O75116 2/20 0.31
ROCK1 Q13464 2/20 0.31
NISCH Q9Y2I1 1/20 0.31
CYP2C9 P11712 1/20 0.31
PRKACA P17612 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501433 0.83 SLC6A2 (0.40) PTGS2NISCHMGLLSLC6A2SLC6A4
SCHEMBL6502262 0.79 ACP3 (0.35) CTSAMAPK1
SCHEMBL7502772 0.77 PNMT (0.42) MAPK14L3MBTL1
SCHEMBL6189088 0.75 PTGDR2 (0.36) MAPK14LOXL2MAPK1
SCHEMBL4312752 0.73 BRAF (0.34) LOXL2KCNH2
SCHEMBL6189080 0.71 KMO (0.36) LOXL2CYP3A4AKT1CYP2D6SLC6A2
Bromide SCHEMBL3887710 0.71 MAPK14 (0.38) MAPK14CTSAPTGS2CYP3A4TSHR
SCHEMBL6468413 0.70
SCHEMBL7247570 0.70 PTGS2 (0.43) PTGS2CYP3A4TSHRMGLLCYP2D6
Bromide SCHEMBL7015383 0.69 MAPK14 (0.34) MAPK14LOXL2NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 MAPK14 50/4885LOXL2 1647/4885NOS3 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.